Skip to main content

Table 2 Breakthrough fungal infections

From: Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study

  AMB Period vs. AZ Period
  AMB (n = 259) AZ (n = 321) Odds Ratio1 p-value2
Any Fungal Infection 27 (10.4%) 44 (13.7%) OR = 1.38 0.23
Possible 18 (6.9%) 37 (11.5%)   
Probable/Definite 9 (3.5%) 7 (2.2%)   
Aspergillus 5 (1.9%) 2 (0.6%) OR = 0.33 0.19
Candida 4 (1.5%) 5 (1.6%) OR = 0.97 0.97
  1. 1Odds ratios are from random effects regression models that controlled for the number of hospitalizations. The reported odds ratios are the odds of having a breakthrough infection in the AZ period relative to the AMB period
  2. 2p-values are from random effects logistic regression models that controlled for the number of hospitalization
  3. *Two patients in the FLU group had both Aspergillus and Candida infections in the same hospitalization
  4. *Of the two patients in the AZ group who had probable/definite breakthrough Aspergillus infection, one patient received FLU and the other received VOR
  5. Note: AMB = amphotericin; AZ = Azole; FLU = fluconazole; VOR = voriconazole